ZAnzalintinib Neoadjuvant EValuation in Thyroid Oncology (ZANEVO)
M.D. Anderson Cancer Center
Summary
To look at the effectiveness of zanzalintinib, followed by surgery, in treating advanced thyroid cancer. The safety of this treatment will also be studied.
Description
Primary Objectives • To evaluate the efficacy of neoadjuvant zanzalintinib in DTC, non-RET-mutated MTC, and poorly differentiated thyroid cancer (PDTC) by overall objective response rate (overall ORR), defined as the proportion of participants who have a minor response (MR), partial response (PR), or complete response (CR) per RECIST. Participants with locally invasive extrathyroidal and/or extra nodal DTC, non- RET-mutated MTC or PDTC who have high surgical morbidity/complexity based on baseline radiographic assessment (as measured by Thyroid Neck Surgical Morbidity/Complexity Scoring, will…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Eligibility Criteria 1. Participants with differentiated thyroid cancer, non-RET-mutated medullary thyroid cancer, or poorly differentiated thyroid cancer who present with locoregionally advanced disease, as defined by extrathyroidal and/or extra nodal extension, or with advanced recurrent/residual invasive/bulky nodal disease will be enrolled in this trial, regardless of whether distant metastases are present or not. 2. At least 18 years of age on the day of signing informed consent. 3. Pathologic findings supporting the clinical impression of papillary thyroid cancer, follicular thyroid can…
Interventions
- DrugZanzalintinib
Given by po
Locations (2)
- Cleveland Clinic Taussig Cancer InstituteCleveland, Ohio
- MD Anderson Cancer CenterHouston, Texas